ABL1 and melanoma: This study seeks to investigate the impact of BCR-ABL tyrosine kinase inhibitors (imatinib, nilotinib, AT-9283, and ZM-306416) on the proliferation of human malignant melanoma A375P cells and unravel the associated mechanisms.